TENX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Tenax Therapeutics Inc (TENX) is not a strong buy at this moment for a beginner investor with a long-term strategy. The stock lacks immediate positive catalysts, has weak technical indicators, and no significant trading signals. While the analyst rating is positive with a raised price target, the company's financials remain weak, and there is no recent news or influential trading activity to support a near-term rally.
The MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 30.498, showing no clear signal. Moving averages are converging, suggesting indecision in price action. The stock is trading near its support level (S2: 10.637), but there is no strong indication of a reversal.
Guggenheim raised the price target to $25 from $14 and reiterated the stock as a Top Pick for 2026, citing progress in its pivotal readout for oral levosimendan in pulmonary hypertension caused by heart failure.
is also down by 0.94%. Technical indicators show bearish momentum. Financials remain weak with no revenue growth and negative net income, despite some YoY improvement.
In Q3 2025, Tenax reported no revenue growth (0% YoY) and a net income of -$15.8M, which improved by 299.04% YoY. EPS improved to -0.4, up 110.53% YoY. However, the company still operates at a loss, with no gross margin.
Guggenheim raised the price target to $25 from $14 and reiterated a Buy rating. The firm considers Tenax a Top Pick for 2026 due to its upcoming pivotal readout for oral levosimendan.
